Wonderful and Powerful CD19 CAR-T Therapy for Cancer Care

Introduction

This CD19-targeted CAR-T cell therapy provides a precise and potent approach to treating CD19-positive cancers, including various forms of lymphoma and leukemia. By using engineered CAR-T cells to specifically target and eliminate cancer cells expressing the CD19 antigen, this technology delivers focused immunotherapy, potentially improving survival rates and reducing side effects. For pharmaceutical and biotech companies in oncology, this CAR-T therapy is an invaluable asset, offering a pathway to develop cutting-edge cancer treatments that align with the growing demand for personalized, effective immunotherapies.

The Challenge: Enhancing Cancer Targeting with Precision

Traditional cancer treatments often struggle with achieving targeted action against cancer cells without impacting healthy tissues, leading to extensive side effects and reduced effectiveness. Patients with CD19-positive cancers face limited treatment options that precisely target cancerous cells, resulting in a need for therapies that combine high efficacy with patient safety. Given the complexities of cancer’s progression, healthcare providers need advanced treatments that address these challenges through innovative, personalized approaches, especially for patients in remission or those with aggressive disease variants.

CAR-T Cells for Precise Cancer Cell Elimination

This CD19-targeted CAR-T therapy technology enables healthcare providers to harness the body’s immune system to specifically target and destroy CD19-positive cancer cells. The therapy’s engineered CAR-T cells seek out and bind to CD19 antigens on cancerous cells, initiating a powerful immune response that eliminates malignancies without harming healthy tissues. Patients benefit from a more precise approach, with the therapy’s high specificity leading to fewer side effects, improved recovery, and enhanced quality of life. The technology’s adaptability to various CD19-positive cancers also broadens its therapeutic reach, supporting a wide range of oncological applications.

Key Benefits for Pharmaceuticals and Oncology Centers

For pharmaceutical developers, this CD19 CAR-T therapy provides a foundation to create a new generation of immunotherapies targeting hematologic cancers with unprecedented precision. Oncology centers can integrate this therapy to offer their patients an advanced, targeted treatment that improves outcomes and supports long-term recovery. This technology aligns with trends in personalized medicine, empowering healthcare providers to deliver patient-centered, tailored care. Its powerful, immune-mediated mechanism makes it a pivotal addition to cancer care, particularly for conditions where conventional therapies fall short.

Invest in the Future of Cancer Treatment

Licensing this CD19 CAR-T therapy technology positions your company at the forefront of immunotherapy and precision oncology. By offering a targeted, effective solution for CD19-positive cancers, your business can drive significant advancements in cancer care. This technology is a strategic investment for companies focused on improving patient outcomes, pioneering new immunotherapy options, and providing transformative cancer treatments that inspire hope and healing.

Please see terms and conditions

Abstract
Claims

Disclosed are compositions and methods for targeted treatment of cancer, such as hematologic cancer. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with hematologic cancer that involves adoptive transfer of the disclosed CAR T cells.

1. A chimeric antigen receptor (CAR) polypeptide, comprising a CD19-binding domain comprising the amino acid sequence set forth in SEQ ID NO:9, a hinge region comprising the amino acid sequence set forth in SEQ ID NO:12, a transmembrane domain comprising the amino acid sequence set forth in SEQ ID NO:13, an intracellular domain comprising the amino acid sequence set forth in SEQ ID NO:14, and an intracellular signaling domain comprising the amino acid sequence set forth in SEQ ID NO:11.

2–9. (canceled)

10. The CAR polypeptide of claim 1, further comprising at least one co-stimulatory signaling region, wherein the co-stimulatory signaling region comprises a signaling domain of any one of the polypeptides CD8, CD3ζ, CD3δ, CD3ε, CD3ε, FcγRI-γ, FcγRIII-γ, FcεRIβ, FcεRIγ, DAP10, DAP12, CD32, CD79a, CD79b, CD28, CD3C, CD4, b2c, CD137 (41BB), ICOS, CD27, CD28δ, CD80, NKp30, OX40, mutants thereof, or any combination thereof.

11–23. (canceled)

24. The CAR polypeptide of claim 1, further comprising a signal peptide comprising the amino acid sequence set forth in SEQ ID NO:8.

25. (canceled)

26. The CAR polypeptide of claim 1, comprising the amino acid sequences set forth in SEQ ID NO:6 or SEQ ID NO:7.

27. (canceled)

28. A nucleic acid encoding the CAR polypeptide of claim 1, wherein the nucleic acid comprises any one of the nucleotide sequences set forth in SEQ ID NOS:1 to 5.

29–30. (canceled)

31. A vector comprising the nucleic acid of claim 28.

32–41. (canceled)

42. A bi-specific chimeric antigen receptor (CAR) T cell expressing;

(a) the CAR polypeptide of claim 26, and

(b) a CAR polypeptide that selectively binds a tumor-associated antigen.

43. (canceled)

44. The bi-specific CAR T cell of claim 42, wherein the tumor-associated antigen is GPC3, MAGE-A1, MAGE-A2, MAGE-C2, SSX-2, Ny-ESO-1, hTERT, or a viral hepatitis antigen.

45–82. (canceled)

83. An immune cell comprising the nucleic acid of claim 28.

84. An immune cell comprising the vector of claim 31.

85. An immune cell expressing the CAR polypeptide of claim 1.

86. The immune cell of claim 85, wherein the immune cell is a lymphocyte selected from an αβT cell, γδT cell, a Natural Killer (NK) cell, a Natural Killer T (NKT) cell, a B cell, an innate lymphoid cell (ILC), a cytokine induced killer (CIK) cell, a cytotoxic T lymphocyte (CTL), a lymphokine activated killer (LAK) cell, a regulatory T cell, or any combination thereof.

87. The immune cell of claim 85, wherein the immune cell is a cytotoxic T lymphocyte (CTL).

88. The immune cell of claim 87, wherein the immune cell is an EBV-antigen sensitized CTL.

89. A method of treating a B-lymphocyte antigen-associated cancer in a subject, the method comprising administering to said subject an effective amount of an adoptive immunotherapy composition comprising CAR-expressing immune cells of claim 85.

90. The method of claim 89, wherein the B-lymphocyte antigen-associated cancer is EBV-associated lymphoproliferative disease.

91. The method of claim 89, wherein the CAR-expressing immune cells of the adoptive immunotherapy composition are derived from the subject.

92. The method of claim 89, wherein the CAR-expressing immune cells of the adoptive immunotherapy composition are not derived from the subject to whom they are administered.

Title

Antigen specific cd19-targeted car-t cells

Inventor(s)

Blake T. Aftab

Assignee(s)

Atara Biotherapeutics Inc

Patent #

20220348649

Patent Date

November 3, 2022